Tumor Immune Profiling to Optimize Clinical Trial Readiness in Basal Cell Nevus Syndrome

肿瘤免疫分析可优化基底细胞痣综合征的临床试验准备

基本信息

项目摘要

SUMMARY Germline mutations in PTCH underlie basal cell nevus syndrome (BCNS), a dominantly inherited disorder also known as Gorlin-Goltz syndrome, in which affected individuals manifest accelerated Hh signaling, leading to inordinate tumor burden that requires multiple, costly and often mutilating surgical procedures. Moreover, BCNS patients develop multiple BCCs in sun-protected areas illustrating their unique tumor susceptibility. Except for tumor-intrinsic Hh signaling, mechanisms underpinning the spontaneous growth and development of BCCs remain unclear. Our group has fostered bench-to-bedside clinical trials with targeted agents in these patients, ultimately leading to FDA approval of the SMO inhibitor (SMOi) vismodegib for treatment of advanced BCCs. Despite substantial anti-tumor efficacy, a major challenge with SMOi has been the emergence of clinical resistance and significant tumor recurrence, as well as intolerable side-effects causing half or more patients to discontinue treatment. Additional preclinical and clinical studies from our group and others clearly indicate that Hh signaling inhibition alone may be necessary but insufficient to permanently eradicate BCCs. This indicates a need to develop novel treatment strategies to ameliorate the limitations of current SMOi’s to improve treatment outcomes. Utilizing our genetically engineered Ptch1+/-/SKH-1 mouse model that faithfully recapitulates the pathogenesis of human BCNS BCCs, we have demonstrated that (i) Hh signaling promotes accumulation of FoxP3+ cells and increases pro-tumorigenic cytokines and chemokines in Ptch1-deficient skin; (ii) SMO inhibition increases CD8+ cells and CXCL10/11, chemokines involved in T cell recruitment; and (iii) treatment of BCC- bearing Ptch1+/-/SKH-1 with anti-PD-1 results in significant tumor regression. These data, together with recent reports showing efficacy of immune checkpoint inhibitors (anti-CTLA4 or anti-PD-1) in human BCCs, strongly support the role of immune mechanisms in BCC growth, and underscore the potential utility of combined SMO and immune checkpoint blockade to reduce tumor burden. To facilitate a future multi-center, single-arm trial of combined therapy of vismodegib and nivolumab (humanized monoclonal anti-PD-1 antibody) in BCNS patients, this application aims to define tumor immune correlates relevant to BCNS microenvironments in Ptch1+/-/SKH-1 mice. In Aim 1, we will characterize immune cell populations and determine the immunologic mechanisms relevant to Hh signaling, and in Aim 2, we will comprehensively define tumor immune profiles and elucidate immunologic correlates predictive of anti-tumor responses to vismodegib and PD-1 blockade.
总结 基底细胞痣综合征(BCNS)是一种显性遗传性疾病, 被称为Gorlin-Goltz综合征,其中受影响的个体表现出加速的Hh信号传导,导致 过度的肿瘤负荷需要多次、昂贵且通常是毁损性的外科手术。此外,BCNS 患者在防晒区域发展出多个BCC,说明他们独特的肿瘤易感性。除了 肿瘤内源性Hh信号,支持基底细胞癌自发生长和发育的机制 仍然不清楚。我们的团队已经在这些患者中进行了靶向药物的临床试验, 最终导致FDA批准SMO抑制剂(SMOi)维莫德吉用于治疗晚期BCC。 尽管具有显著的抗肿瘤功效,但SMOi的主要挑战是临床肿瘤的出现。 耐药性和显著的肿瘤复发,以及无法忍受的副作用,导致一半或更多的患者 停止治疗。我们小组和其他人的其他临床前和临床研究清楚地表明, 单独的Hh信号传导抑制可能是必要的,但不足以永久根除BCC。这表明 需要开发新的治疗策略,以改善目前SMOi的局限性,以改善治疗 结果。利用我们的基因工程Ptch 1 +/-/SKH-1小鼠模型,忠实地再现了 在人类BCNS BCC的发病机制中,我们已经证明了(i)Hh信号传导促进 FoxP 3+细胞,并增加Ptch 1缺陷皮肤中的促肿瘤细胞因子和趋化因子;(ii)SMO抑制 增加CD 8+细胞和CXCL 10/11,参与T细胞募集的趋化因子;和(iii)治疗BCC- 携带Ptch 1 +/-/SKH-1和抗PD-1的肿瘤细胞导致显著的肿瘤消退。这些数据,加上最近 报告显示免疫检查点抑制剂(抗CTLA 4或抗PD-1)在人BCC中的疗效, 支持免疫机制在BCC生长中的作用,并强调联合SMO的潜在效用 和免疫检查点阻断以减少肿瘤负荷。为了促进未来的多中心,单组试验, 维莫德吉和纳武单抗(人源化单克隆抗PD-1抗体)在BCNS患者中的联合治疗, 本申请旨在定义与Ptch 1 +/-/SKH-1中的BCNS微环境相关的肿瘤免疫相关物 小鼠在目标1中,我们将描述免疫细胞群并确定免疫机制 在目标2中,我们将全面定义肿瘤免疫特征并阐明 预测对维莫德吉和PD-1阻断的抗肿瘤应答的免疫学相关性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID RINSEY BICKERS其他文献

DAVID RINSEY BICKERS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID RINSEY BICKERS', 18)}}的其他基金

Molecular Mechanisms Underlying the Prevention of BCC Resistance
预防 BCC 耐药性的分子机制
  • 批准号:
    10552026
  • 财政年份:
    2020
  • 资助金额:
    $ 20.25万
  • 项目类别:
Molecular Mechanisms Underlying the Prevention of BCC Resistance
预防 BCC 耐药性的分子机制
  • 批准号:
    10330598
  • 财政年份:
    2020
  • 资助金额:
    $ 20.25万
  • 项目类别:
Molecular Mechanisms Underlying the Prevention of BCC Resistance
预防 BCC 耐药性的分子机制
  • 批准号:
    9974157
  • 财政年份:
    2020
  • 资助金额:
    $ 20.25万
  • 项目类别:
Tumor Immune Profiling to Optimize Clinical Trial Readiness in Basal Cell Nevus Syndrome
肿瘤免疫分析可优化基底细胞痣综合征的临床试验准备
  • 批准号:
    10221074
  • 财政年份:
    2020
  • 资助金额:
    $ 20.25万
  • 项目类别:
Columbia University Skin Disease Resource-Based Center (epiCURE)
哥伦比亚大学皮肤病资源中心 (epiCURE)
  • 批准号:
    9087989
  • 财政年份:
    2016
  • 资助金额:
    $ 20.25万
  • 项目类别:
Columbia University Skin Disease Resource-Based Center (epiCURE)
哥伦比亚大学皮肤病资源中心 (epiCURE)
  • 批准号:
    9765045
  • 财政年份:
    2016
  • 资助金额:
    $ 20.25万
  • 项目类别:
Non-melanoma skin cancer: A model for impact of aging on an environmental disease
非黑色素瘤皮肤癌:衰老对环境疾病影响的模型
  • 批准号:
    9204120
  • 财政年份:
    2016
  • 资助金额:
    $ 20.25万
  • 项目类别:
Mechanism-based abrogation of BCC pathogenesis
基于机制的 BCC 发病机制的消除
  • 批准号:
    8460080
  • 财政年份:
    2012
  • 资助金额:
    $ 20.25万
  • 项目类别:
Mechanism-based abrogation of BCC pathogenesis
基于机制的 BCC 发病机制的消除
  • 批准号:
    8610310
  • 财政年份:
    2012
  • 资助金额:
    $ 20.25万
  • 项目类别:
Mechanism-based abrogation of BCC pathogenesis
基于机制的 BCC 发病机制的消除
  • 批准号:
    8296459
  • 财政年份:
    2012
  • 资助金额:
    $ 20.25万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 20.25万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 20.25万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.25万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.25万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.25万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 20.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 20.25万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 20.25万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 20.25万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 20.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了